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Preventative ibandronate treatment has the most benefi cial effect on 
the microstructure of bone in experimental tumor osteolysis
Abstract We investigated the effect of ibandronate on 
three-dimensional (3-D) microstructure and bone mass in 
experimentally induced tumor osteolysis. Walker carcino-
sarcoma cells were implanted into the left femur of female 
rats that received 26-day ibandronate pretreatment fol-
lowed by continued therapy or ibandronate posttreatment 
only. A tumor-only group received isotonic saline. At end-
point, excised femurs were scanned using microcomputed 
tomography (µCT) to assess bone volume density, bone 
mineral content, trabecular number/thickness, and separa-
tion for cortical plus trabecular bone or trabecular bone 
alone. Compared with the nonimplanted right femur, bone 
volume and surface density and trabecular number and 
thickness were reduced in the distal left femur following 
tumor cell implantation. µCT analysis revealed greater cor-
tical and trabecular bone mineral content in the preventa-
tive and interventional (pre-post tumor) ibandronate group, 
and the interventional (post-tumor) ibandronate group, 
versus the tumor-only group. Bone volume density was 
signifi cantly higher in pre-post and post-tumor groups 
compared to the tumor-only group. After preventative and 
interventional ibandronate, bone volume density and tra-
becular thickness were 13% and 60% greater, respectively, 
than in the post-tumor treatment group. 3-D µCT images 
confi rmed microstructural changes. We conclude that 
combined interventional and preventative ibandronate pre-
serves bone strength and integrity more than intervention 
alone.
Key words bisphosphonate · preclinical · computer tomog-
raphy · skeletal integrity
Introduction
Skeletal metastases are the most frequent complication of 
malignant tumors and are associated with severe pain and 
pathological fractures. Although treatment for metastatic 
bone lesions does not alter life expectancy, preventing frac-
tures can improve the quality of life of the cancer patient. 
Bisphosphonates are one class of therapeutic agents cur-
rently being used or under investigation for various dis-
eases related to pathologically increased bone resorption, 
such as Paget’s disease, postmenopausal osteoporosis, and 
tumor-induced hypercalcemia and osteolysis [1]. Over re-
cent years, bisphosphonates have also become an estab-
lished treatment for bone metastases, and are currently the 
only available treatment option for bone complications as-
sociated with malignancies. Bisphosphonates are able to 
reduce the number of skeletal complications by inhibiting 
osteoclast-mediated bone destruction. Numerous experi-
mental and clinical studies have shown that interventional 
treatment can reduce the occurrence of pathological frac-
tures, bone pain, hypercalcemia, and the need for radio-
therapy and surgery [2].
Preclinical studies and initial clinical experience show 
that preventative administration of bisphosphonates seems 
very promising and more benefi cial for the patient than 
palliative administration alone [3–9]. Investigations into 
the use of bisphosphonates are now directed to understand 
the effects of a preventative treatment on tumor osteolysis 
[10]. A recent investigation on bone quality in tumor 
osteolysis showed that tumor growth in bone resulted in a 
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decrease in bone mass and the loss of biomechanical com-
petence of bone, but they are not correlated [11]. In addi-
tion, new imaging techniques for determining the alteration 
of the three-dimensional (3-D) structure of trabecular 
bone, a factor known to infl uence its mechanical behavior, 
have been introduced [12].
We utilized this new technology in a previous study and 
demonstrated that microcomputed tomography (µCT) can 
provide 3-D parameters of bone mass and trabecular struc-
ture in an animal model for tumor-induced bone loss [13]. 
We found signifi cant differences in 3-D morphometric pa-
rameters between the tumor-bearing bones and contralat-
eral controls.
In the current experimental study, we investigated the 
effect of a preventative administration of ibandronate on 
the 3-D microstructure of bone in a rat model for tumor-
induced osteolysis. Building on previously published ex-
periments [11,13–15], this study aimed to investigate 
whether interventional treatment with ibandronate affects 
the tumor-induced destruction of the 3-D structure of tra-
becular bone, and whether preventative treatment com-
bined with interventional treatment preserves the 3-D 
structure of trabecular bone in tumor osteolysis better than 
interventional treatment alone.
Materials and methods
Animal model and treatment protocol
We used a previously described animal model to evaluate 
densitometric and biomechanical properties in tumor oste-
olysis [11,13–15]. The widely used Walker Carcinosarcoma 
256 malignant breast cancer cells (W256) were cultured in 
0.6% agarose gel solution. After anesthesia by an intraperi-
toneal injection of ketamine hydrochloride (75 mg/kg) and 
xylazine (5 mg/kg), equivalent volumes of tumor cells in 
agarose gel containing approximately 2 × 106 cells were 
surgically implanted into the medullary canal of the left 
femur via a drill hole in the intercondylar notch (see [15] 
for additional details). Forty-fi ve female Sprague–Dawley 
rats aged 4 months were randomly assigned to three 
study groups. All animals were maintained in accordance 
with federal regulations, and the study was conducted with 
the approval of the Institutional Animal Care and Use 
Committee (Harvard Medical School). In the fi rst group 
(tumor-only), Walker 256 tumor cells were implanted into 
the left femur without treatment. The second group (pre-
post) fi rst underwent a daily pretreatment with ibandronate 
(Roche Diagnostics, Mannheim, Germany; 25 µg/kg sub-
cutaneously) for 26 days; then, tumor cells were implanted 
and the daily treatment was continued until death. The 
third group (post) received daily ibandronate treatment 
only after tumor cell implantation. There were no compli-
cations from the surgical procedure. Twenty-eight days 
after surgery, all animals were killed and both femora from 
each rat were harvested and cleaned of soft tissue for image 
analysis. Before microtomographic scanning, all femora 
were radiographed in an anteroposterior plane using a 
Faxitron machine (Hewlett-Packard, McMinnville, OR, 
USA).
Structural analysis using microcomputed tomography 
(µCT)
As in our recent study [13], we employed a desktop µCT 
imaging system (µCT 20; Scanco Medical, Bassersdorf, 
Switzerland: 30 µm, nominal resolution) to assess 3-D den-
sitometric and architectural parameters in small animal 
whole bones. The µCT system has a micro-X-ray source 
(10 µm focal spot, 25 keV) directed toward the sample. The 
quantitative modifi cation of the X-ray beam by apatite 
crystals contained in the bone sample is analyzed by a 
plane detector (CCD array; 1024 elements). The process is 
piloted by an Alpha workstation (HP, Palo Alto, CA, USA) 
and an OpenVMS system in cluster confi guration to per-
form the 3-D analysis. For each specimen, a total of 200 
microtomographic slices were taken, each 30 µm thick, 
starting from a reproducible anatomical landmark right 
behind the boundary of the condyles, thereby covering a 
6-mm region of the distal femur. From the obtained two-
dimensional slices, 3-D reconstruction of bone was auto-
matically performed using the triangulation algorithm. 
Architectural indices were calculated in the spherical vol-
ume of interest according to standard defi nitions used in 
histomorphometry [11]. Bone volume density (bone vol-
ume/tissue volume), bone surface density (bone surface/
bone volume), trabecular thickness, trabecular separation, 
and trabecular number were determined directly from the 
3-D images. Bone mineral content, calculated using the 
measured bone volume and assuming a constant tissue 
density, was measured in a metaphyseal region consisting 
of both cortical and trabecular bone, and a sphere consist-
ing of trabecular bone only. In a previous study, calcula-
tions of bone mineral content using this method were 
shown to correlate closely to dual-energy X-ray absorpti-
ometry (DXA)-based methods [16], and in a separate 
study, the bone volume densities of metastatic cancer bone 
and normal bone were found to be similar [17]. A total of 
90 specimens (left and right femora) were scanned. All 90 
specimens were analyzed using both visual assessment and 
quantitative morphometry.
Statistical analysis
A Wilk–Shapiro test for normality was conducted on all 
parameters. All data were expressed as the mean ± stan-
dard deviation. Analysis of variance (ANOVA) with 
Student–Newman–Keuls post hoc analysis, or a paired t 
test was performed to determine if the measurements dif-
fered signifi cantly (statistical signifi cance level, P < 0.05).
Results
This model of tumor induction in bone has been character-
ized previously [11,13–15]. As with previous studies, 
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radiographs confi rmed that all femora implanted with tu-
mor cells contained osteolytic lesions [11,15]. In addition, 
there was macroscopic evidence of soft tissue tumors sur-
rounding affected bones.
Compared with the nonimplanted right femur, bone vol-
ume density, bone surface density, trabecular number, and 
trabecular thickness were signifi cantly reduced in the dis-
tal left femur following the implantation of tumor cells 
(P < 0.001). Trabecular separation was signifi cantly in-
creased in the left femur (Table 1).
The µCT analysis revealed greater values for cortical 
and trabecular bone mineral content in the preventative 
and interventional (pre-post tumor) ibandronate treatment 
group, and the interventional (post-tumor) ibandronate 
treatment group, than in the tumor-only group (Table 2). 
Morphometric analysis of trabecular volume revealed 
architectural changes in accordance with the quantitative 
changes seen in bone density (Figs. 1–4).
Changes in architectural parameters of the left femur 
following treatment with ibandronate are summarized in 
Table 3. Bone volume density was signifi cantly higher in 
the pre-post and post-tumor groups compared to the 
tumor-only group, showing an increase of 133% and 106%, 
respectively (P < 0.05) (Table 3). These results are most 
likely caused by a signifi cant increase in trabecular thick-
ness (up by 211% and 95% versus the tumor-only group, 
respectively; P < 0.05) (Table 3). In addition, trabecular 
separation signifi cantly decreased in the pre-post (−74%) 
Table 1. Architectural parameters of the distal left (implanted) and right (nonimplanted) femur (no ibandronate treatment)
Group (n) Bone volume Bone surface Trabecular Trabecular Trabecular
 density (%) density (mm2/mm3) number (1/mm) thickness (mm) separation (mm)
Left femur (15)  33.78 (11.30)   6.66 (1.72)   2.79 (1.03)   0.09 (0.01)  0.33 (0.21)
Right femur (15)  48.24 (5.95)   8.41 (0.64)   3.69 (0.51)   0.10 (0.02)  0.18 (0.05)
Group differences (%) −30* −21* −24* −10* 83*
Data are means (SD)
* P < 0.001 (paired t test)
Table 2. Bone mineral content for full and trabecular regions in the 
left operated femur measured using micro-computed tomography 
(µCT)
Groupa (n) Full bone Trabecular bone
 mineral content mineral content
Pre-post (15)  0.17 (0.02)   0.07 (0.01)
Post (15)  0.16 (0.02)   0.06 (0.01)
Tumor only (15)  0.10 (0.02)   0.02 (0.01)
Group differences (%)
 Pre-post vs. tumor only 74* 174*
 Pre-post vs. post 11*  21*
 Post vs. tumor only 57* 127*
Data are mean in grams (SD)
a Group title indicates treatments received: pre-post, ibandronate 
administered both before and after tumor cell implantation; post, 
ibandronate administered after tumor implantation but not before; 
tumor only, tumor implantation with no ibandronate treatment (see 
Materials and methods for further details)
* P < 0.05 (ANOVA with Student–Newman–Keuls post hoc 
comparisons)
Fig. 1. Three-dimensional (3-D) reconstruction of microcomputed 
tomography (µCT) slices for a control bone with no tumor and pla-
cebo treatment (a 6-mm region is shown)
Fig. 2. 3-D reconstruction of µCT slices for a tumor-bearing bone 
with placebo treatment (a 6-mm region is shown)
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Fig. 3. 3-D reconstruction of µCT slices for a tumor-bearing 
bone with interventional ibandronate treatment (a 6-mm region is 
shown)
Fig. 4. 3-D reconstruction of µCT slices for a tumor-bearing bone 
with preventative and interventional ibandronate treatment (a 6-mm 
region is shown)
Table 3. Architectural parameters of the distal left (operated) femur measured using microcomputed tomography (µCT)
Groupa (n) Bone volume Bone surface Trabecular Trabecular Trabecular
 density (%) density (mm2/mm3) number (1/mm) thickness (mm) separation (mm)
Pre-post (15)  78.58 (4.52)   5.83 (0.85)   2.80 (0.52)   0.28 (0.07)   0.09 (0.02)
Post (15)  69.52 (7.32)   7.49 (0.61)   3.77 (0.37)   0.18 (0.04)   0.09 (0.02)
Tumor only (15)  33.78 (11.30)   6.66 (1.72)   2.79 (1.03)   0.09 (0.01)   0.33 (0.21)
Group differences (%)
 Pre-post vs. tumor
  only 133* −12   0 211* −74*
 Pre-post vs. post  13* −22* −26*  60*  −3
 Post vs. tumor only 106*  12  35*  95* −73*
Data are mean (SD)
a Group title indicates treatments received: pre-post, ibandronate administered both before and after tumor cell implantation; post, ibandro-
nate administered after tumor implantation but not before; tumor only, tumor implantation with no ibandronate treatment (see Materials 
and methods for further details)
* P < 0.05 (ANOVA with Student–Newman–Keuls post hoc comparisons)
and post-tumor (−73%) treatment groups (P < 0.05 versus 
tumor only) (Table 3).
Values recorded in the pre-post ibandronate treatment 
group were 13% greater for bone volume density and 60% 
greater for trabecular thickness than in the post-tumor 
treatment group (P < 0.05) (Table 3). Bone surface density 
and trabecular number were not affected by ibandronate 
treatment (see Table 3).
Discussion
The aim of the present study was to investigate the 
effect of a bisphosphonate, ibandronate, on bone density 
and 3-D bone structure in a rat model of tumor-induced 
osteolysis. Previously, we presented biomechanical and 
mineralization data with this model and treatment regi-
men, including DXA-based measurements, and also dem-
onstrated no effects on serum calcium with the ibandronate 
doses used [11]. Other studies have also demonstrated that 
ibandronate does not induce either hypomineralization or 
hypermineralization, even at doses exceeding any thera-
peutically intended dose by multiples [11,18,19].
From clinical experience, it is known that bone metas-
tases frequently occur in the metaphyseal regions of long 
bones and the vertebral bodies of the spine. In those areas, 
the turnover rate of trabecular bone is much greater than 
that of cortical bone; consequently, dramatic changes in 
tumor osteolysis occur in trabecular bone much later than 
in cortical bone. This also is the region of bone where the 
effect of an interventional treatment with bisphosphonates 
is more pronounced [20,21]. In recent years, 3-D analysis 
of bone has become possible using µCT technology. This 
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tool rapidly evaluates the internal morphology and struc-
ture of trabecular and cortical bone, and has been widely 
used in osteoporosis research and to examine the effects of 
pharmacological intervention on bone [12,22–27]. In par-
ticular, µCT imaging allows the noninvasive examination 
of the quantity, orientation, and connection of trabecular 
bone elements separately from cortical bone by focusing 
on a selected volume of interest containing trabecular bone 
only.
The results of the present study confi rm that ibandro-
nate administered either as a daily interventional treat-
ment starting after the onset of tumor growth in bone, or 
as both a preventative and interventional treatment, pre-
serves bone mass and 3-D structure compared with an un-
treated tumor-only control group. However, we found a 
greater benefi cial effect on density, mineral content, and 
trabecular thickness in the preventative and interventional 
ibandronate group than the intervention-only group. In a 
previous study, we found that preventative and interven-
tional treatment increased failure load by 9% versus inter-
ventional treatment alone in this model, although this was 
not statistically signifi cant [11]. These data may suggest a 
potential for preventative ibandronate treatment to reduce 
the risk of fractures for patients. The similar number of 
trabeculae in the treatment groups indicates that ibandro-
nate affected mostly existing trabeculae (i.e., increasing 
their width) rather than inducing formation of new trabec-
ulae. These results are corroborated by two recent in vivo 
studies of bisphosphonate action on trabecular microarchi-
tecture: a macaque study of preventative ibandronate for 
ovariectomy-induced bone loss in the lumbar spine [16], 
and a human trial of risedronate for preserving iliac bone 
architecture in postmenopausal women with osteoporosis 
[28]. In both studies, trabecular number was preserved and 
trabecular thickness was increased in treatment groups 
compared with controls or baseline values.
Several studies in different experimental models have 
shown that preventative bisphosphonate treatment reduces 
the development of bone metastases. Preventative etidro-
nate treatment reduced osteolysis and prolonged survival 
in a rat model of bone metastasis using bladder carcinoma 
cells [29]. In other studies using parathyroid hormone-
related protein-producing Walker 256 carcinosarcoma cells 
inoculated intraosseously into rats, pretreatment with clo-
dronate or pamidronate was osteoprotective, with the ex-
tent of the effect correlating with duration and intensity of 
treatment [7–9,30]. Preventative treatment with pamidro-
nate was also shown to increase trabecular volume, al-
though an increase in skeletal tumor burden was observed, 
with no effects on nonosseous metastases [6]. However, 
other studies of human breast carcinoma cells injected into 
nude mice have shown a reduced tumor burden following 
pretreatment with ibandronate [31] or risedronate [32]. In 
addition, in a similar rat model, risedronate pretreatment 
decreased the incidence of bone metastases with no effect 
on visceral metastases [4]. Previous studies performed in 
our laboratory showed that combined preventative and 
interventional treatment with ibandronate most effec-
tively preserved bone mass and strength, although all 
ibandronate treatment schedules resulted in signifi cant im-
provements compared with untreated tumor-bearing con-
trols [11,14]. Supporting these results, a recent study of 
experimentally induced multiple tumor osteolysis in rats 
found that initiation of ibandronate therapy 3 days before 
tumor cell inoculation substantially reduced the develop-
ment of osteolytic lesions compared with postoperative 
ibandronate administration [33].
Our study did not investigate the mechanism of action 
for the observed benefi ts of preventative ibandronate treat-
ment. Bisphosphonates have several potential inhibitory 
effects on bone metastases. In particular, these agents have 
a well-documented inhibitory effect on osteoclast function. 
Studies have shown that bisphosphonates induce apoptosis 
in murine osteoclasts both in vivo and in vitro, and a great-
er effect is seen with more potent agents [34,35]. In addi-
tion, bisphosphonates may promote the secretion of an 
osteoclast inhibitory factor by osteoblasts [36]. Bisphos-
phonates also induce apoptosis in macrophages [37,38] and 
human myeloma cell lines [39] in vitro. Other biological 
effects include inhibiting the adhesion of breast or prostate 
carcinoma cells to bone matrices [40,41], inhibiting matrix 
metalloproteinases in vitro and in vivo, and decreasing the 
invasive properties of malignant melanoma and fi brosar-
coma cell lines [31,42].
In a previous study from our laboratory, we assessed 
the effects of preventative and interventional ibandronate 
treatment on nonimplanted femora [11]. As is well estab-
lished, ibandronate increased various bone parameters 
(such as bone mineral density) in femora without tumors; 
however, the effects were less than those observed in 
tumor-implanted femora. Although this confi rms that 
ibandronate has additional effects on tumor-containing 
bone, it is unclear whether this is a result of timing of treat-
ment or total dose administered. Regardless of mechanism, 
the present study further demonstrates that combined pre-
ventative and interventional ibandronate treatment is most 
benefi cial in our model, and this fi nding has direct rele-
vance to clinical dosing.
Conclusions
In our animal model investigating the structural conse-
quences of tumor destruction in trabecular bone, both 
ibandronate treatment schedules resulted in signifi cantly 
greater bone mass and improved structural parameters 
compared with no treatment. Combined preventative and 
continued treatment provided the best protection against 
tumor-mediated bone destruction and preserved the integ-
rity of bone, even in the presence of a malignant tumor. 
Our experimentally obtained results for bone structure are 
in concordance with accumulating clinical evidence sug-
gesting that preventative treatment with bisphosphonates 
can reduce the occurrence of skeletal complications in can-
cer patients and thus may prolong survival [43,44]. These 
animal experiments and the current clinical experience 
with bisphosphonates suggest that further investigations 
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that focus on preventative treatment are likely to be very 
promising.
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